Developing breakthrough treatments for fibrotic diseases

Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.

Year Invested: 2016
Location: Redwood, Calif.

Recent News

April 9, 2019
Pliant Therapeutics Reports Positive Results on Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis

March 28, 2019
Pliant Therapeutics Presents Data In Human Nash Liver Tissue At The International Liver Congress 2019 Hosted By The European Association For The Study Of The Liver (EASL)

March 14, 2019
Pliant Therapeutics Appoints Smital Shah To Its Board Of Directors

Read More News

Associated Team Members

Neil Exter

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.